Asthma, Exercise-Induced Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Asthma, Exercise-Induced Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Asthma, Exercise-Induced; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Asthma, Exercise-Induced receives an overall strategic score of 65/100. The opportunity combines an unmet-need score of 80/100, competition score of 75/100 and market-attractiveness score of 77/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

Asthma attacks following a period of exercise. Usually the induced attack is short-lived and regresses spontaneously. The magnitude of postexertional airway obstruction is strongly influenced by the environment in which exercise is performed (i.e. inhalation of cold air during physical exertion markedly augments the severity of the airway obstruction; conversely, warm humid air blunts or abolishes it).

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Asthma, Exercise-Induced, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID fb4264a7c1d246d09ce5304462f401c1 and MeSH identifier D001250. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Epidemiology of adult asthma within the Hungarian population between 2009 and 2019 – A retrospective financial database analysis Global Epidemiology Epidemiology of adult asthma within the Hungarian population between 2009 and 2019 – A retrospective financial database analysis

Incident cases were identified based on prescription and treatment history: if a patient had no prescription for any medication nor had in-, or outpatient care with the ICD-20 code of asthma, before a given year, they were considered incident cases for that year. As we had no data before 2009, incidence was not evaluated for 2009 and 2010, taking into consideration that treatment cessation due to low adherence can be quite common. As there are many patients with mild asthma who might not need a prescription every year, it was decided that the first two years of the study, incidence will not be evaluated to increase accuracy.i Severe exacerbations were defined as a need for hospitalization due to asthma. Hospitalizations were considered related to asthma if the ICD-10 code of asthma was recorded as the main cause for inpatient care in the hospital records. Costs of care were calculated from the diagnosis- related group (DRG) value of COPD care. To compare prevalence of asthma in each year, the publicly available database of the Hungarian Central Statistics Office was used, in order to calculate the number of adult populations in Hungary. [21] The costs of hospitalizations for asthma are shown in EUR exchanges on the average exchange rate of EUR to HUF in 2009, according to the database of the European Central Bank. [22] Only descriptive statistics were used to present data. Results Prevalence and incidence

Review the underlying epidemiology source

Evidence signal 2: Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15–39 years): an analysis based on the global burden of disease study 2021

the highest ASPR for Asthma in AYAs (11475.50 [8546.43 to 14889.22]), followed by Portugal (9743.81 [6784.71 to 13047.20]) and Iceland (8095.78 [5667.93 to 10944.44]), while the lowest ASPR were in Nepal (643.77 [480.07 to 835.44]), Bhutan (789.94 [578.00 to 1050.99]), and Leso­ tho (832.21 [652.92 to 1043.44]) (Fig. 9. A, B, C & Table S4-6). Asthma in AYAs demonstrated significant decreas­ ing trends all regions (AAPC < 0 and P < 0.05), with the largest decreases observed in the European Region. At the national level, only the United States of America ‘s ASIR for Asthma in AYAs exhibits a statistically signifi­ cant upward trend (AAPC = 0.79 [95% CI: 0.58 to 1.00]), while the largest decrease occurred in South Africa (-3.00 [-3.13 to -2.87]), followed by Singapore (-2.63 [-2.92 to -2.33]) and Russian Federation (-2.60 [-2.70 to -2.51]). The United States of America had the largest increase in ASPR for Asthma in AYAs (0.60 [0.43 to 0.78]), fol­ lowed by Guyana (0.18 [0.14 to 0.23]), and Belize (0.04 From 1990 to 2021, the ASIR (AAPC=-0.96 [95% CI: -1.03 to -0.88]), ASPR (AAPC=-1.25 [-1.31 to -1.19]), and ASMR (-1.35 [-1.44 to -1.26]) of Asthma in AYAs globally showed a significant decreasing trend (Fig. 10). At the regional level, the ASIR, ASPR, and ASMR of Fig. 9 ASIR, ASPR and ASMR of Asthma in AYAs at the national level in 2021 (A, B, C), and their changing trends from 1990 to 2021 (D, E, F)

Review the underlying epidemiology source

Evidence signal 3: China CDC Weekly Reports (Vol. 7 No. 27 Jul. 4, 2025) Investigation of a Thunderstorm Asthma Event— Chongqing Municipality, China, April 2024

Beggs PJ. Thunderstorm asthma and climate change. JAMA 2024;331 (10):878 − 9. https://doi-org.libproxy1.nus.edu.sg/10.1001/jama.2023.26649. 1. Zou E, Worsham C, Miller NH, Molitor D, Reif J, Jena AB. Emergency visits for thunderstorm-related respiratory illnesses among older adults. JAMA Intern Med 2020;180(9):1248 − 50. https://doi. org/10.1001/jamainternmed.2020.1672. 2. Jia RM, Liu XY, Xu WY, Liu J. Thunderstorm asthma and related mechanism: a review of recent studies. J Environ Health 2024;41(12): 1114 − 8. https://doi-org.libproxy1.nus.edu.sg/10.16241/j.cnki.1001-5914.2024.12.015. 3. Lin SJ, Wang F, Hao YQ, Tang HP. Interpretation of the guidelines for the prevention and control of bronchial asthma (2020 edition). Chin J Clin 2022;50(12):1406-8. http://dx.doi.org.libproxy1.nus.edu.sg/10.3969/j.issn.2095-8552. 2022.12.006. (In Chinese). 4. Packe GE, Ayres JG. Asthma outbreak during a thunderstorm. Lancet 1985;2(8448):199 − 204. https://doi-org.libproxy1.nus.edu.sg/10.1016/s0140-6736(85) 91510-7. 5. Thien F, Beggs PJ, Csutoros D, Darvall J, Hew M, Davies JM, et al. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planet Health 2018;2(6):e255 − 63. https:// doi.org/10.1016/S2542-5196(18)30120-7. 6. Xu YY, Xue T, Li HR, Guan K. Retrospective analysis of epidemic thunderstorm asthma in children in Yulin, Northwest China. Pediatr Res 2021;89(4):958 − 61. https://doi-org.libproxy1.nus.edu.sg/10.1038/s41390-020-0980-9. 7. Yan M, Jin QP, Chu JJ, Na JR. Investigation and analysis of a thunderstorm asthma. Ningxia Med J 2023;45(3):270-3. http://dx.doi. org/10.13621/j.1001-59

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Asthma, Exercise-Induced, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Asthma, Exercise-Induced should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: IL-6

IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4(+) T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4(+) T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells (By similarity). Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:12794819, PubMed:17075861). Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819). Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453). 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity). Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity). Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity). Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).

The proposed mechanism anchor for this landscape is IL6. Target selection does not imply that every Asthma, Exercise-Induced patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 115 matched registered studies overall. The most recent records sampled for this report are:

• NCT07466849 — Hypoxic Environment on EIB and Performance in Race Walkers (EIB-H); status: Completed; phase: Not Applicable; sponsor(s): not stated; enrollment: 64.
• ChiCTR2600120102 — Epidemiological Investigation of Exercise - Induced Bronchoconstriction among Elite Athletes in Chongqing; status: Pending; phase: Not Applicable; sponsor(s): not stated; enrollment: 260.
• NCT06702735 — The Rainbow Study - the Effect of Feedback on Asthmatic Symptom Perception; status: Recruiting; phase: Not Applicable; sponsor(s): Medisch Spectrum Twente; enrollment: 39.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Asthma, Exercise-Induced program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Asthma, Exercise-Induced. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Asthma, Exercise-Induced.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Asthma, Exercise-Induced, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that IL6 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Asthma, Exercise-Induced merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where IL6 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Asthma, Exercise-Induced offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.